Literature DB >> 11927183

Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.

Sudabeh Shirazi-Southall1, Dana Ellen Rodriguez, George G Nomikos.   

Abstract

Some atypical antipsychotic drugs appear to improve cognitive function in schizophrenia and since acetylcholine (ACh) is of importance in cognition, we used in vivo microdialysis to examine the effects of antipsychotics administered acutely (SC or IP) at pharmacologically comparable doses on ACh outflow in the hippocampus of the rat. The atypical antipsychotics olanzapine and clozapine produced robust increases in ACh up to 1500% and 500%, respectively. The neuroleptics haloperidol, thioridazine, and chlorpromazine, as well as the atypical antipsychotics risperidone and ziprasidone produced modest increases in ACh by about 50-100%. Since most atypical antipsychotics affect a variety of monoaminergic receptors, we examined whether selective ligands for some of these receptors affect hippocampal ACh. Antagonists for the 5-HT(2A) (MDL 100,907), the 5-HT(2C) (SB 242,084), the 5-HT(6) (Ro 04-6790), the D(2) (raclopride) receptors, and the alpha(1)-adrenoceptors (prazosin) modestly increased ACh by about 50%. The 5-HT(1A) agonist R-(+)-8-OH-DPAT and the alpha(2)-adrenoceptor antagonist yohimbine significantly increased ACh by about 100% and 50%, respectively. Thus, olanzapine and clozapine increased ACh to a greater extent than other tested antipsychotics, explaining perhaps their purported beneficial effect in cognitive function in schizophrenia. It appears that selective activity at each of the monoaminergic receptors studied is not the sole mechanism underlying the olanzapine and clozapine induced increases in hippocampal ACh.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927183     DOI: 10.1016/S0893-133X(01)00400-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  53 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Cognitive effects of olanzapine treatment in schizophrenia.

Authors:  Susan R McGurk; M A Lee; K Jayathilake; Herbert Y Meltzer
Journal:  MedGenMed       Date:  2004-05-10

3.  Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats.

Authors:  Ramakrishna Nirogi; Gopinadh Bhyrapuneni; Vishwottam Kandikere; Vijay Benade; Nageswararao Muddana; Ramanatha Saralaya; Shantaveer Irappanavar; Ranjithkumar Ponnamaneni; K Mukkanti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-02-03       Impact factor: 2.441

Review 4.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 5.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 6.  Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.

Authors:  Jue He; Jiming Kong; Qing-Rong Tan; Xin-Min Li
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

9.  Tolerance to the procholinergic action of the D1 receptor full agonist dihydrexidine.

Authors:  Mark R Wade; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Acute and chronic effects of clozapine on cholinergic transmission in cultured mouse superior cervical ganglion neurons.

Authors:  Taixiang Saur; Bruce M Cohen; Qi Ma; Suzann M Babb; Edgar A Buttner; Wei-Dong Yao
Journal:  J Neurogenet       Date:  2016-09-14       Impact factor: 1.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.